A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

NCT07241039 · clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
220
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

AbbVie